The Role of ADAMTS-4 in Atherosclerosis and Vessel Wall Abnormalities.

IF 1.8 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Journal of Vascular Research Pub Date : 2022-01-01 Epub Date: 2022-01-20 DOI:10.1159/000521498
Rudjer Novak, Stela Hrkac, Grgur Salai, Josko Bilandzic, Luka Mitar, Lovorka Grgurevic
{"title":"The Role of ADAMTS-4 in Atherosclerosis and Vessel Wall Abnormalities.","authors":"Rudjer Novak,&nbsp;Stela Hrkac,&nbsp;Grgur Salai,&nbsp;Josko Bilandzic,&nbsp;Luka Mitar,&nbsp;Lovorka Grgurevic","doi":"10.1159/000521498","DOIUrl":null,"url":null,"abstract":"<p><p>Extracellular matrix proteins are regulated by metzincin proteases, like the disintegrin metalloproteinases with thrombospondin motifs (ADAMTS) family members. This review focuses on the emerging role which ADAMTS-4 might play in vascular pathology, which has implications for atherosclerosis and vessel wall abnormalities, as well as for the resulting diseases, such as cardiovascular and cerebrovascular disease, aortic aneurysms, and dissections. Major substrates of ADAMTS-4 are proteoglycans expressed physiologically in smooth muscle cells of blood vessels. Good examples are versican and aggrecan, principal vessel wall proteoglycans that are targeted by ADAMTS-4, driving blood vessel atrophy, which is why this metzincin protease was implicated in the pathophysiology of vascular diseases with an atherosclerotic background. Despite emerging evidence, it is important not to exaggerate the role of ADAMTS-4 as it is likely only a small piece of the complex atherosclerosis puzzle and one that could be functionally redundant due to its high structural similarity to other ADAMTS family members. The therapeutic potential of inhibiting ADAMTS-4 to halt the progression of vascular disease after initialization of treatment is unlikely. However, it is not excluded that it might find a purpose as a biomarker of vascular disease, possibly as an indicator in a larger cytokine panel.</p>","PeriodicalId":17530,"journal":{"name":"Journal of Vascular Research","volume":"59 2","pages":"69-77"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000521498","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 11

Abstract

Extracellular matrix proteins are regulated by metzincin proteases, like the disintegrin metalloproteinases with thrombospondin motifs (ADAMTS) family members. This review focuses on the emerging role which ADAMTS-4 might play in vascular pathology, which has implications for atherosclerosis and vessel wall abnormalities, as well as for the resulting diseases, such as cardiovascular and cerebrovascular disease, aortic aneurysms, and dissections. Major substrates of ADAMTS-4 are proteoglycans expressed physiologically in smooth muscle cells of blood vessels. Good examples are versican and aggrecan, principal vessel wall proteoglycans that are targeted by ADAMTS-4, driving blood vessel atrophy, which is why this metzincin protease was implicated in the pathophysiology of vascular diseases with an atherosclerotic background. Despite emerging evidence, it is important not to exaggerate the role of ADAMTS-4 as it is likely only a small piece of the complex atherosclerosis puzzle and one that could be functionally redundant due to its high structural similarity to other ADAMTS family members. The therapeutic potential of inhibiting ADAMTS-4 to halt the progression of vascular disease after initialization of treatment is unlikely. However, it is not excluded that it might find a purpose as a biomarker of vascular disease, possibly as an indicator in a larger cytokine panel.

ADAMTS-4在动脉粥样硬化和血管壁异常中的作用。
细胞外基质蛋白受metzincin蛋白酶调控,如具有凝血反应蛋白基序(ADAMTS)家族成员的崩解素金属蛋白酶。这篇综述的重点是ADAMTS-4可能在血管病理学中发挥的新作用,这可能涉及动脉粥样硬化和血管壁异常,以及由此导致的疾病,如心脑血管疾病、主动脉瘤和夹层。ADAMTS-4的主要底物是血管平滑肌细胞生理性表达的蛋白聚糖。很好的例子是versican和aggrecan, ADAMTS-4靶向的主要血管壁蛋白聚糖,驱动血管萎缩,这就是为什么这种metzincin蛋白酶与动脉粥样硬化背景的血管疾病的病理生理有关。尽管有新的证据,但重要的是不要夸大ADAMTS-4的作用,因为它可能只是复杂动脉粥样硬化之谜的一小部分,而且由于其与其他ADAMTS家族成员的高度结构相似性,它可能在功能上是多余的。抑制ADAMTS-4在初始治疗后停止血管疾病进展的治疗潜力不太可能。然而,不排除它可能作为血管疾病的生物标志物,可能作为一个更大的细胞因子面板的指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Vascular Research
Journal of Vascular Research 医学-生理学
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
>12 weeks
期刊介绍: The ''Journal of Vascular Research'' publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation. JVR''s ''Vascular Update'' series regularly presents state-of-the-art reviews on hot topics in vascular biology. Manuscript processing times are, consistent with stringent review, kept as short as possible due to electronic submission. All articles are published online first, ensuring rapid publication. The ''Journal of Vascular Research'' is the official journal of the European Society for Microcirculation. A biennial prize is awarded to the authors of the best paper published in the journal over the previous two years, thus encouraging young scientists working in the exciting field of vascular biology to publish their findings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信